Hi [[ session.user.profile.firstName ]]

Different TTF-1 clones for the diagnosis of lung tumors: primary vs. metastatic

Dr. Sonja Klebe of SA Pathology and Flinders University, Australia, will share data from two recently published studies investigating immunohistochemistry using various TTF-1 clones for diagnosis of lung cancer and metastases of other origins. She will discuss the sensitivity and specificity of the different TTF-1 clones and the resulting implications in identifying lung, prostate, and colorectal adenocarcinomas.
Recorded Dec 18 2019 36 mins
Your place is confirmed,
we'll send you email reminders
Presented by
A/Prof. Dr. Sonja Klebe, MD, PhD, FRCPA
Presentation preview: Different TTF-1 clones for the diagnosis of lung tumors: primary vs. metastatic

Network with like-minded attendees

  • [[ session.user.profile.displayName ]]
    Add a photo
    • [[ session.user.profile.displayName ]]
    • [[ session.user.profile.jobTitle ]]
    • [[ session.user.profile.companyName ]]
    • [[ userProfileTemplateHelper.getLocation(session.user.profile) ]]
  • [[ card.displayName ]]
    • [[ card.displayName ]]
    • [[ card.jobTitle ]]
    • [[ card.companyName ]]
    • [[ userProfileTemplateHelper.getLocation(card) ]]
  • Channel
  • Channel profile
  • Demystifying Cancer Immunology Oct 22 2020 3:00 pm UTC 60 mins
    Dr. Josef Kurtz, Professor of Biology, Chief Academic Officer at Emmanuel College in Boston, MA
    The interplay between the immune system and cancer remains one of the biggest enigmas and opportunities in medicine. During this webinar, we will review the basic tenants of how the immune system is organized and functions, as well as the major components (antibodies, T cells, signaling pathways, etc.). The goal of this webinar is to better understand how a system so exquisitely tuned and effective in defending our bodies from pathogens can be so challenged when the disease is of our own cells.
  • Computational Pathology & Quantitative Biomarkers of the Tumor Microenvironment Oct 15 2020 3:00 pm UTC 60 mins
    Dr. Lee Cooper, Associate Professor of Pathology, Northwestern University Feinberg School of Medicine
    Computational pathology tools can aid in deciphering features of the tumor microenvironment in whole-slide images of cancer specimens. Digital pathology will generate petabytes of data over the coming decade, and quantitative and high-resolution descriptions of tissue morphology linked with clinical and genomic data can help to inform diagnostic criteria and advance understanding of disease and treatment. This talk will describe development of machine learning tools for dense high-resolution mapping of tissue components, including the generation of data for training and validation, and will discuss implications for the future practice of pathology and research.
  • Digital Pathology: Current and Future Benefits Using PD-L1 as the Paradigm Recorded: Aug 27 2020 60 mins
    Dr. Alex Haragan, Pathologist MRC Clinical Research Fellow at Royal Liverpool University Hospital, Liverpool, England
    This webinar will give an overview of the Roche uPath software with particular regards to digital slide image viewing and the use of the PD-L1 immunohistochemistry interpretation algorithm. The pros and cons of digital pathology and uPath will be considered, with a focus on the use of the PD-L1 algorithm and how this can be used to augment pathologists' ability to interpret this tricky predictive biomarker in the context of NSCLC.
  • Module 3: Ventana PD-L1 (SP263) Assay NSCLC Guided Digital Case Review Recorded: Jul 24 2020 71 mins
    Dr. Dorothy Hayden, Pathologist at Roche Tissue Diagnostics
    This series of videos is provided as a resource for individuals in countries where VENTANA PD-L1 (SP263) Assay is approved for use for non-small cell lung cancer (NSCLC).

    Please refer to the respective drug labeling for clinical recommendations pertaining to PD-L1 expression.

    These videos feature Roche Tissue Diagnostics Pathologist, Dr. Dorothy Hayden, and are intended to be a refresher for pathologists and laboratories on VENTANA PD-L1 (SP263) Assay in NSCLC. Module 1 is a PD-L1 and PD-L1 (SP263) assay overview , Module 2 discusses evaluation guidance for PD-L1 (SP263) assay in NSCLC, and Module 3 is a PD-L1 (SP263) Guided Digital NSCLC Case Review.
  • Module 2: Ventana PD-L1 (SP263) Assay NSCLC Evaluation Education Recorded: Jul 24 2020 18 mins
    Dr. Dorothy Hayden, Pathologist at Roche Tissue Diagnostics
    This series of videos is provided as a resource for individuals in countries where VENTANA PD-L1 (SP263) Assay is approved for use for non-small cell lung cancer (NSCLC).

    Please refer to the respective drug labeling for clinical recommendations pertaining to PD-L1 expression.

    These videos feature Roche Tissue Diagnostics Pathologist, Dr. Dorothy Hayden, and are intended to be a refresher for pathologists and laboratories on VENTANA PD-L1 (SP263) Assay in NSCLC. Module 1 is a PD-L1 and PD-L1 (SP263) assay overview , Module 2 discusses evaluation guidance for PD-L1 (SP263) assay in NSCLC, and Module 3 is a PD-L1 (SP263) Guided Digital NSCLC Case Review.
  • Module 1: Ventana PD-L1 (SP263) NSCLC Assay Overview Recorded: Jul 24 2020 11 mins
    Dr. Dorothy Hayden, Pathologist at Roche Tissue Diagnostics
    This series of videos is provided as a resource for individuals in countries where VENTANA PD-L1 (SP263) Assay is approved for use for non-small cell lung cancer (NSCLC).

    Please refer to the respective drug labeling for clinical recommendations pertaining to PD-L1 expression.

    These videos feature Roche Tissue Diagnostics Pathologist, Dr. Dorothy Hayden, and are intended to be a refresher for pathologists and laboratories on VENTANA PD-L1 (SP263) Assay in NSCLC. Module 1 is a PD-L1 and PD-L1 (SP263) assay overview , Module 2 discusses evaluation guidance for PD-L1 (SP263) assay in NSCLC, and Module 3 is a PD-L1 (SP263) Guided Digital NSCLC Case Review.
  • The Pathologist in the Era of Immunotherapy Recorded: Jul 23 2020 61 mins
    Dr. Ken Bloom
    The job of the pathologist is crucial in the era of precision medicine and immunotherapy. Pathologists need not only to correctly diagnose and classify tumors, but also aid in the selection of the best treatment strategies based on the presence or absence of critical biomarkers. Because tumors are heterogeneous, this includes discussion with the interventionalist about which lesions to sample in metastatic disease and selection of the best area of tumor for analysis in resections. While next generation sequencing techniques provide a plethora of data about mutations, gene expression and copy number, the pathologist must interpret these results in the context of the histologic appearance of the sample. In this webinar, Dr. Bloom will review the challenges faced by pathologists today with the emergence of immunotherapy and explain the critical role of the pathologist in assessing the tumor and its microenvironment.
  • Breast Cancer Diagnostics Practical Considerations and What's On the Horizon Recorded: Jul 16 2020 62 mins
    Dr. Sunil Badve
    Breast cancer is the most commonly occurring cancer in women with over two-million newly diagnosed patients worldwide in 2018. At the molecular level, breast cancer is a heterogeneous disease. Precision medicine and targeted therapies have a long history in the diagnosis and treatment of breast cancer. Early-stage breast cancer is now a curable disease in the majority of patients but advanced breast cancer remains largely incurable. The identification of new actionable targets continues to drive the development of innovative therapeutic approaches in breast cancer. This webinar will review a series of three breast cancer patients providing a practical approach to diagnostic testing and share perspectives on future testing options and precision pathology.
  • Lung Cancer Diagnostics: Evolving Practice and Future Directions Recorded: May 21 2020 61 mins
    Professor Keith Kerr
    Personalized medicine for non-small-cell lung cancer (NSCLC) continues to evolve rapidly, building on a solid diagnostic foundation based on H&E and immunohistochemistry (IHC), incorporating predictive biomarker testing for oncogene-directed therapies and immunotherapies. Understanding the role of biomarker testing, different technologies and latest developments is vitally important for practicing pathologists.

    During this Bright TALK webinar, Professor Keith Kerr will review the current diagnostic pathways in lung cancer, outline the role of IHC and molecular testing, differentiate oncogene biomarkers from immunotherapy biomarkers, and share his perspectives on future directions in lung cancer testing, including multiplexed assays.
  • Understanding genome-wide NIPT Recorded: May 12 2020 57 mins
    Dr. Liza Kunz and Jen Kaplan, LCGC
    Cell-free DNA prenatal test menus have rapidly expanded in recent years to address not only the common trisomies, but also sex chromosome aneuploidies, copy number variants, and rare autosomal trisomies. However, “more” is not necessarily “better”. Potential benefits to patients must be carefully weighed against potential harms before tests are introduced into clinical practice. Please join us for an in-depth examination of clinical considerations and implications of expanded cfDNA test menus.
  • Clinical decision support in the NGS Oncology workflow Recorded: May 7 2020 56 mins
    Dr. Stephanie Yaung
    The increasing adoption of next generation sequencing (NGS) in molecular profiling of cancer presents a need for streamlined result interpretation in clinical labs. With growing complexity of NGS results, evolving guidelines, and fragmented data sources, clinical decision support (CDS) systems can facilitate reporting of clinically relevant variants. In this talk, our speaker will discuss how software capable of automatically interpreting and presenting clinically relevant information reduces the need for time-consuming and error-prone manual curation.
  • OMG Twins? NIPT for multiple pregnancy Recorded: Apr 30 2020 49 mins
    Renee Jones, LCGC
    Pregnancies with more than one fetus are not uncommon. cfDNA analysis of twin pregnancies is confounded by unique technical and biological factors. This talk will review published data for the prenatal use of cfDNA analysis in twin pregnancies and highlight clinical considerations that influence the use of this approach for aneuploidy risk assessment.
  • Molecular testing along the cancer patient journey Recorded: Apr 23 2020 59 mins
    Dr. John Jiang
    Molecular testing has been becoming one of the critical components of modern clinical oncology patient care. There are various types of tests that provide tumor biomarker information ranging from a single marker to a few hundred markers. How to utilize these tests will depend on the type of diseases and specific indication.
  • Controversies in cell-free DNA testing: Maternal cancer and NIPT Recorded: Apr 16 2020 49 mins
    Jennifer Kaplan, MS, LCGC
    Recent publications regarding the ability of NIPT to detect maternal malignancy have captured the attention of the media as well as medical providers and patients. Although case reports of the detection of maternal cancer can be compelling, there are significant harms associated with using NIPT to screen for maternal cancer. Please join us for an educational webinar on this topic, where we will examine the available data and clinical considerations regarding NIPT as a screen for maternal cancer.
  • ISH & IHC multiplexing in metabolic disease research with DISCOVERY ULTRA Recorded: Apr 9 2020 59 mins
    Dr. Aaron Mercer, Dr. Alan Moghaddam
    Learn more about applications of ISH & IHC multiplexing with RNAscope and next-generation chromogenic staining on DISCOVERY ULTRA system.
  • Different TTF-1 clones for the diagnosis of lung tumors: primary vs. metastatic Recorded: Dec 18 2019 36 mins
    A/Prof. Dr. Sonja Klebe, MD, PhD, FRCPA
    Dr. Sonja Klebe of SA Pathology and Flinders University, Australia, will share data from two recently published studies investigating immunohistochemistry using various TTF-1 clones for diagnosis of lung cancer and metastases of other origins. She will discuss the sensitivity and specificity of the different TTF-1 clones and the resulting implications in identifying lung, prostate, and colorectal adenocarcinomas.
  • The ROSING Study: A New ROS1 IHC Clone (SP384) for ROS1 Rearrangements Recorded: Nov 25 2019 41 mins
    Fernando Lopez-Rios, MD, PhD, FIAC
    The Lopez-Rios lab and their colleagues throughout Spain have published a very informative study (The ROSING Study) on ROS1 in Journal of Thoracic Oncology. Dr. Fernando Lopez-Rios will be presenting the data from the manuscript and be available for questions following his live presentation.
  • NTRK Rearrangements in Oncology: Diagnostic Strategies and Therapeutic Relevance Recorded: Nov 21 2019 62 mins
    Dr. Eric Konnick
    In this webinar, Dr. Konnick will discuss the biology, background and
    rationale for targeting TRK fusions. You will learn about the clinical
    evidence for TRK inhibitors and issues implementing pan-tumor assays,
    specifically pan-TRK assays.
  • Panel Discussion-Prioritizing Testing in the Context of Predictive Markers Recorded: May 1 2019 9 mins
    Panel Discussion
    Panel Discussion-Prioritizing Testing in the Context of Predictive Markers hosted by Dr. Paul A. Bunn Jr, MD. Panel participants include Dr. Philippe Taniere, MD, PhD, Dr. Erik Thunnissen, FBJM, and Dr Emd (Ed) Schuuring, Prof Dr.
  • Panel Discussion-Making Appropriate Diagnosis in Lung Cancer Recorded: May 1 2019 28 mins
    Panel Discussion
    Panel Discussion-Making Appropriate Diagnosis in Lung Cancer with Dr. Paul A. Bunn Jr, MD,as your host. The panel includes Dr. Corrado D'Arrigo, MBChB, PhD, FRCPath, Dr. Mark Kockx, MD, PhD, and Dr. Erik Thunnissen, FBJM.
DIASights from Roche
This series is brought to you by Roche. We are committed to providing you with educational content, from key opinion leaders, related to personalized diagnostics. We aim to ensure on ongoing conversation is taking place in this evolving area of healthcare.

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry eight years in a row by the Dow Jones Sustainability Indices.

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2015 employed more than 91,700 people worldwide. In 2015, Roche invested CHF 9.3 billion in R&D and posted sales of CHF 48.1 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

Embed in website or blog

Successfully added emails: 0
Remove all
  • Title: Different TTF-1 clones for the diagnosis of lung tumors: primary vs. metastatic
  • Live at: Dec 18 2019 9:30 pm
  • Presented by: A/Prof. Dr. Sonja Klebe, MD, PhD, FRCPA
  • From:
Your email has been sent.
or close